Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Engelman

Showing results (31-40 of 238) with videos related to

Pageof 24
Sort By:
Journal of Virology|September 1, 1994
The core and carboxyl-terminal domains of the integrase protein of human immunodeficiency virus type 1 each contribute to nonspecific DNA bindingA Engelman, A B Hickman, R Craigie
Journal of Virology|October 9, 1999
Structure-based mutagenesis of the human immunodeficiency virus type 1 DNA attachment site: effects on integration and cDNA synthesisH E Brown, H Chen, A Engelman
The EMBO Journal|August 1, 1993
Identification of discrete functional domains of HIV-1 integrase and their organization within an active multimeric complexA Engelman, F D Bushman, R Craigie
Nature Reviews. Genetics|July 19, 2006
The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolismJeffrey A Engelman, Ji Luo, Lewis C Cantley
Cancer Discovery|May 16, 2012
A new BATTLE in the evolving war on cancerLecia V Sequist, Alona Muzikansky, Jeffrey A Engelman
Journal of Virology|December 1, 1996
Reversion of a human immunodeficiency virus type 1 integrase mutant at a second site restores enzyme function and virus infectivityB Taddeo, F Carlini, P Verani, et al.
Oncotarget|April 21, 2011
Potential therapeutic strategies to overcome acquired resistance to BRAF or MEK inhibitors in BRAF mutant cancersRyan B Corcoran, Jeffrey Settleman, Jeffrey A Engelman
FEBS Letters|November 4, 1998
Genes encoding human caveolin-1 and -2 are co-localized to the D7S522 locus (7q31.1), a known fragile site (FRA7G) that is frequently deleted in human cancersJ A Engelman, X L Zhang, M P Lisanti
Cell Cycle (Georgetown, Tex.)|December 25, 2008
Overcoming resistance to tyrosine kinase inhibitors: lessons learned from cancer cells treated with EGFR antagonistsBrent N Rexer, Jeffrey A Engelman, Carlos L Arteaga
The Journal of Biological Chemistry|November 21, 1998
Specific inhibitors of p38 mitogen-activated protein kinase block 3T3-L1 adipogenesisJ A Engelman, M P Lisanti, P E Scherer
Pageof 24

Showing results (31-40 of 238) with videos related to

Sort By:
Pageof 24
Journal of Virology|September 1, 1994
The core and carboxyl-terminal domains of the integrase protein of human immunodeficiency virus type 1 each contribute to nonspecific DNA bindingA Engelman, A B Hickman, R Craigie
Journal of Virology|October 9, 1999
Structure-based mutagenesis of the human immunodeficiency virus type 1 DNA attachment site: effects on integration and cDNA synthesisH E Brown, H Chen, A Engelman
The EMBO Journal|August 1, 1993
Identification of discrete functional domains of HIV-1 integrase and their organization within an active multimeric complexA Engelman, F D Bushman, R Craigie
Nature Reviews. Genetics|July 19, 2006
The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolismJeffrey A Engelman, Ji Luo, Lewis C Cantley
Cancer Discovery|May 16, 2012
A new BATTLE in the evolving war on cancerLecia V Sequist, Alona Muzikansky, Jeffrey A Engelman
Journal of Virology|December 1, 1996
Reversion of a human immunodeficiency virus type 1 integrase mutant at a second site restores enzyme function and virus infectivityB Taddeo, F Carlini, P Verani, et al.
Oncotarget|April 21, 2011
Potential therapeutic strategies to overcome acquired resistance to BRAF or MEK inhibitors in BRAF mutant cancersRyan B Corcoran, Jeffrey Settleman, Jeffrey A Engelman
FEBS Letters|November 4, 1998
Genes encoding human caveolin-1 and -2 are co-localized to the D7S522 locus (7q31.1), a known fragile site (FRA7G) that is frequently deleted in human cancersJ A Engelman, X L Zhang, M P Lisanti
Cell Cycle (Georgetown, Tex.)|December 25, 2008
Overcoming resistance to tyrosine kinase inhibitors: lessons learned from cancer cells treated with EGFR antagonistsBrent N Rexer, Jeffrey A Engelman, Carlos L Arteaga
The Journal of Biological Chemistry|November 21, 1998
Specific inhibitors of p38 mitogen-activated protein kinase block 3T3-L1 adipogenesisJ A Engelman, M P Lisanti, P E Scherer
Pageof 24